迈向临床治愈：慢性乙型肝炎治疗药物的 进展与展望
Advancing Towards Clinical Cure: Progress and Prospects in Therapeutics for Chronic Hepatitis B
DOI: 10.12677/acm.2026.1631063, PDF,   
作者: 杜雷雷, 贾怡敏：延安大学延安医学院，陕西 延安；高晓红*：延安大学附属医院感染病科，陕西 延安
关键词: 慢性乙型肝炎；抗病毒治疗；临床治愈；联合治疗；Chronic Hepatitis B； Antiviral Therapy； Clinical Cure； Combined Treatment
摘要: 随着高效核苷(酸)类似物(NAs)的应用，长期病毒抑制与并发症风险降低已成为现实。聚乙二醇干扰素α (PEG-IFNα)则为部分患者开启了一扇实现有限疗程临床治愈的大门。当前临床决策的核心已转向精细化的个体管理，涵盖初治方案选择、经治患者的联合治疗优化及特殊人群的个体化策略。尽管现有疗法显著改善了疾病预后，但实现广泛的功能性治愈仍是未竟之业。本文系统综述了目前临床主要抗病毒药物的药理特性、疗效与安全性，总结了临床治疗策略与监测管理，并展望了以新型直接抗病毒药物(如RNAi疗法)和免疫疗法为代表的未来研究方向，旨在为实现CHB的“有限疗程”和更高治愈率提供参考。
Abstract: With the application of highly effective nucleoside (acid) analogues (NAs), long-term viral suppression and reduced risk of complications have become a reality. Pegylated interferon alpha (PEG-IFNα) has opened a door for some patients to achieve clinical cure with a limited course of treatment. The core of current clinical decision-making has shifted to refined individualized management, including the selection of initial treatment regimens, the optimization of combined treatments for treated patients, and individualized strategies for special populations. Although existing therapies have significantly improved disease prognosis, achieving widespread functional cure remains an unmet goal. This article systematically reviews the pharmacological properties, efficacy, and safety of the main antiviral drugs currently used in clinical practice, summarizes clinical treatment strategies and monitoring management, and looks forward to future research directions represented by new direct antiviral drugs (such as RNAi therapy) and immunotherapy, aiming to provide a reference for achieving “Limited treatment course” and higher cure rates in chronic hepatitis B (CHB).
文章引用：杜雷雷, 贾怡敏, 高晓红. 迈向临床治愈：慢性乙型肝炎治疗药物的 进展与展望[J]. 临床医学进展, 2026, 16(3): 2635-2643. https://doi.org/10.12677/acm.2026.1631063

参考文献

[1] Sun, J. and Guo, J. (2025) Global, Regional, and National Burden of Chronic Hepatitis B-Related Cirrhosis from 1990 to 2021 and Projections to 2050: A Finding from the Global Burden of Disease Study 2021. Clinical and Translational Gastroenterology, 16, e00890. [Google Scholar] [CrossRef] [PubMed]
[2] Tenney, D.J., Rose, R.E., Baldick, C.J., Pokornowski, K.A., Eggers, B.J., Fang, J., et al. (2009) Long-Term Monitoring Shows Hepatitis B Virus Resistance to Entecavir in Nucleoside-Naïve Patients Is Rare through 5 Years of Therapy #. Hepatology, 49, 1503-1514. [Google Scholar] [CrossRef] [PubMed]
[3] Marcellin, P., Heathcote, E.J., Buti, M., Gane, E., de Man, R.A., Krastev, Z., et al. (2008) Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B. New England Journal of Medicine, 359, 2442-2455. [Google Scholar] [CrossRef] [PubMed]
[4] Agarwal, K., Brunetto, M., Seto, W.K., Lim, Y., Fung, S., Marcellin, P., et al. (2018) 96 Weeks Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Hepatitis B Virus Infection. Journal of Hepatology, 68, 672-681. [Google Scholar] [CrossRef] [PubMed]
[5] Buti, M., Gane, E., Seto, W.K., Chan, H.L.Y., Chuang, W., Stepanova, T., et al. (2016) Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate for the Treatment of Patients with HbeAg-Negative Chronic Hepatitis B Virus Infection: A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial. The Lancet Gastroenterology & Hepatology, 1, 196-206. [Google Scholar] [CrossRef] [PubMed]
[6] Boni, C., Laccabue, D., Lampertico, P., Giuberti, T., Viganò, M., Schivazappa, S., et al. (2012) Restored Function of Hbv-Specific T Cells after Long-Term Effective Therapy with Nucleos(t)ide Analogues. Gastroenterology, 143, 963-973.e9. [Google Scholar] [CrossRef] [PubMed]
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版) [J]. 中华肝脏病杂志, 2022, 30(12): 1309-1331.
[8] Moreau, R., Tonon, M., Krag, A., Angeli, P., Berenguer, M., Berzigotti, A., et al. (2023) EASL Clinical Practice Guidelines on Acute-on-Chronic Liver Failure. Journal of Hepatology, 79, 461-491. [Google Scholar] [CrossRef] [PubMed]
[9] Terrault, N.A., Lok, A.S.F., McMahon, B.J., Chang, K., Hwang, J.P., Jonas, M.M., et al. (2018) Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67, 1560-1599. [Google Scholar] [CrossRef] [PubMed]
[10] Ning, Q., Han, M., Sun, Y., Jiang, J., Tan, D., Hou, J., et al. (2014) Switching from Entecavir to PegIFN Alfa-2a in Patients with HbeAg-Positive Chronic Hepatitis B: A Randomised Open-Label Trial (OSST Trial). Journal of Hepatology, 61, 777-784. [Google Scholar] [CrossRef] [PubMed]
[11] Pan, C.Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., et al. (2016) Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. New England Journal of Medicine, 374, 2324-2334. [Google Scholar] [CrossRef] [PubMed]
[12] Gish, R.G., Clark, M.D., Kane, S.D., Shaw, R.E., Mangahas, M.F. and Baqai, S. (2012) Similar Risk of Renal Events among Patients Treated with Tenofovir or Entecavir for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 10, 941-946. [Google Scholar] [CrossRef] [PubMed]
[13] Liu, Z., Jin, Q., Zhang, Y., Gong, G., Wu, G., Yao, L., et al. (2021) Randomised Clinical Trial: 48 Weeks of Treatment with Tenofovir Amibufenamide versus Tenofovir Disoproxil Fumarate for Patients with Chronic Hepatitis B. Alimentary Pharmacology & Therapeutics, 54, 1134-1149. [Google Scholar] [CrossRef] [PubMed]
[14] Papatheodoridis, G.V., Idilman, R., Dalekos, G.N., Buti, M., Chi, H., van Boemmel, F., et al. (2017) The Risk of Hepatocellular Carcinoma Decreases after the First 5 Years of Entecavir or Tenofovir in Caucasians with Chronic Hepatitis B. Hepatology, 66, 1444-1453. [Google Scholar] [CrossRef] [PubMed]
[15] Sonneveld, M.J., Hansen, B.E., Piratvisuth, T., Jia, J., Zeuzem, S., Gane, E., et al. (2013) Response-Guided Peginterferon Therapy in Hepatitis B E Antigen-Positive Chronic Hepatitis B Using Serum Hepatitis B Surface Antigen Levels. Hepatology, 58, 872-880. [Google Scholar] [CrossRef] [PubMed]
[16] Lok, A.S.F., McMahon, B.J., Brown, R.S., Wong, J.B., Ahmed, A.T., Farah, W., et al. (2015) Antiviral Therapy for Chronic Hepatitis B Viral Infection in Adults: A Systematic Review and Meta‐Analysis. Hepatology, 63, 284-306. [Google Scholar] [CrossRef] [PubMed]
[17] Jonas, M.M., Chang, M., Sokal, E., Schwarz, K.B., Kelly, D., Kim, K.M., et al. (2015) Randomized, Controlled Trial of Entecavir versus Placebo in Children with Hepatitis B Envelope Antigen-Positive Chronic Hepatitis B. Hepatology, 63, 377-387. [Google Scholar] [CrossRef] [PubMed]
[18] Fung, J., Cheung, C., Chan, S., Yuen, M., Chok, K.S.H., Sharr, W., et al. (2011) Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus after Liver Transplantation. Gastroenterology, 141, 1212-1219. [Google Scholar] [CrossRef] [PubMed]
[19] Yuen, M., Zhou, X., Gane, E., Schwabe, C., Tanwandee, T., Feng, S., et al. (2021) Safety, Pharmacokinetics, and Antiviral Activity of RO7049389, a Core Protein Allosteric Modulator, in Patients with Chronic Hepatitis B Virus Infection: A Multicentre, Randomised, Placebo-Controlled, Phase 1 Trial. The Lancet Gastroenterology & Hepatology, 6, 723-732. [Google Scholar] [CrossRef] [PubMed]
[20] Yuen, M., Heo, J., Jang, J., Yoon, J., Kweon, Y., Park, S., et al. (2021) Safety, Tolerability and Antiviral Activity of the Antisense Oligonucleotide Bepirovirsen in Patients with Chronic Hepatitis B: A Phase 2 Randomized Controlled Trial. Nature Medicine, 27, 1725-1734. [Google Scholar] [CrossRef] [PubMed]
[21] Bazinet, M., Pântea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., et al. (2020) Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients with Chronic HBV Infection Naïve to Nucleos(t)ide Therapy. Gastroenterology, 158, 2180-2194. [Google Scholar] [CrossRef] [PubMed]
[22] Boni, C., Vecchi, A., Rossi, M., Laccabue, D., Giuberti, T., Alfieri, A., et al. (2018) TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Gastroenterology, 154, 1764-1777.e7. [Google Scholar] [CrossRef] [PubMed]
[23] Lok, A.S., Zoulim, F., Dusheiko, G. and Ghany, M.G. (2017) Hepatitis B Cure: From Discovery to Regulatory Approval. Journal of Hepatology, 67, 847-861. [Google Scholar] [CrossRef] [PubMed]
[24] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版) [J]. 中华肝脏病杂志, 2015, 23(12): 888-905.
[25] Wang, J., Shen, T., Huang, X., Kumar, G.R., Chen, X., Zeng, Z., et al. (2016) Serum Hepatitis B Virus RNA Is Encapsidated Pregenome RNA That May Be Associated with Persistence of Viral Infection and Rebound. Journal of Hepatology, 65, 700-710. [Google Scholar] [CrossRef] [PubMed]
[26] Lu, F., Wang, J., Chen, X., Xu, D. and Xia, N. (2017) Potential Use of Serum HBV RNA in Antiviral Therapy for Chronic Hepatitis B in the Era of Nucleos(t)ide Analogs. Frontiers of Medicine, 11, 502-508. [Google Scholar] [CrossRef] [PubMed]
[27] Revill, P.A., Chisari, F.V., Block, J.M., Dandri, M., Gehring, A.J., Guo, H., et al. (2019) A Global Scientific Strategy to Cure Hepatitis B. The Lancet Gastroenterology & Hepatology, 4, 545-558. [Google Scholar] [CrossRef] [PubMed]

为你推荐